Alpibectir

N/A

Report date: 2026/03/30 20:02:02
NMEQIDP

Base Information

Drug NameAlpibectir
Drug Alias NameBVL-GSK098BDM-14500BDM-31381BDM-3143BDM-41420 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTranscription factors inhibitors
TargetsTranscription factors
Therapy Area/IndicationsTuberculosis, PulmonaryTuberculosis, Multidrug-ResistantTuberculosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth AfricaSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBioVersys AGGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesTask Applied ScienceGlaxosmithkline PlcBioVersys AG
Inactive CompaniesN/A
Active IndicationsTuberculosis, PulmonaryTuberculosis, Multidrug-ResistantTuberculosis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A